Noveris Health Sciences (STU:0NF1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0NF1 Noveris Health Sciences Inc STU:0NF1
34 GF Score
Price €1.05
GF Value €0.39
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:0NF1
34GF Score
Noveris Health Sciences Inc STU:0NF1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Noveris Health Sciences (STU:0NF1) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of €1.05 is trading 169.2% above its estimated GF Value™ of €0.39. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for STU:0NF1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.39 vs. price of €1.05 (169.2% above fair value)
  • GF Score™: 34/100

No single metric tells the full story. See the STU:0NF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noveris Health Sciences Business Description

Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
34GF Score

Get the complete analysis for STU:0NF1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price
€0.39
GF Value